Rite Aid, Albertsons call off merger; AMA disapproves of CVS-Aetna deal; FDA signs off on first generic drug for CGT designation.
Matt McNally, CEO of Outcome Health, shares his thoughts on post-controversy Outcome Health and the overall state of the point-of-care union.
The partnership will give Kyne a presence in Mexico, Argentina, and Colombia.
Trump promises move to lower drug prices; CVS, Novo Nordisk beat earnings predictions; AstraZeneca settles two suits with Texas for $110 million.
Among the group's members are media agencies that had pulled healthcare ad spend from the POC channel in the wake of a scandal 10 months ago.
Alderman is reporting to Varsha Rao, Clover's COO
Icahn asks Cigna investors to reject $54 billion Express Scripts deal; FDA changes opioid treatment evaluation; GSK names CFO.
Analysts from Jefferies predicted up to $2 billion in peak sales if Amarin's seven-year trial data is positive.
Regeneron invests $100 million in bluebird; Boehringer Ingelheim starts cystic fibrosis coalition; FDA rejects Pain Therapeutics' application to sell Remoxy.
After a scandal with one of point of care's biggest players, we examine how the community is living up to its promise of greater transparency.
He's filling the newly created role of EVP of integrated analytics and innovation for the agency's Chicago health practice.
Allergan sues Pfizer to cover costs of opioid lawsuits; Drug companies donate millions to areas hit by the opioid crisis; Mayo Clinic: Opioid prescriptions not decreasing.
Two late-stage orphan drugs are upping the ante with their promise to cure disease.
Alissa Kaplan, executive director, healthcare, at J. Walter Thompson, discusses work-life balance and how she manages her day.
The organization worked with Finn Partners to create the #BeTheGift campaign.
Lead Tecentriq scientist resigns; Apple hires for on-site health clinic; Novo launches DTC diabetes campaign.
Credera - like consultancies - has direct access to Fortune 500 C-suite execs.
Despite a rash of pessimism, HCPs remain engageable. Marketers must utilize open medical education hubs and CME town halls — among other tactics — to make content more engaging.
Mary Manna Anderson has joined Haymarket to lead its medical education business.
Pfizer CEO says rebates to go away; Ispos to acquire four GfK research divisions; Sanofi promises to return to growth in 2H 2018.
HCPs are still OK with hearing from pharma and medical device marketers as long as it's by email.
'Long way to go' before top pharma companies' digital presence measures up to current tech standards: study
A cross section of pharma brand websites fell short across all measured areas, including consumer experience, technology, SEO, and analytics, researchers said.
GSK consumer healthcare chief digital officer Marc Speichert talks about being a builder.
Historical big earners once again performed for Pfizer in Q2, while Ibrance broke the $1 billion barrier.
Pfizer lowers full-year forecast; Bayer to sell prescription dermatology brands to Leo; behind July's healthcare agency M&A boom.
At least six in 10 marketing chiefs globally are expecting growth in their budgets in the coming year, with 73% of UK chief marketing officers predicting a boost.
Study: Few patients use price-comparison tools to shop for lower-limb MRIs; Ascletis raises $400 million in Hong Kong IPO; California bucks trend on maternal death rates.
The agency brought on Lisa Wolfington to lead the group as director of health system marketing.
AstraZeneca promises to not raise drug prices this year; EHR adoption could lower hospital death rates: study; Roche's new drugs drive earnings.
The channel will feature content about the full range of the cancer journey.
Astellas shook up its corporate affairs department after Winton's departure.
Facebook sought to blame GDPR as it revealed its daily active users in Europe declined for the first time in nine years and it disappointed investors with lower-than-expected growth.
Alzheimer's drug slows cognitive decline; Gilead CEO to leave; Amgen migraine drug face difficulties with insurers.
Full-page Purdue print ad amended; GSK partners with 23andMe; AbbVie's endometriosis drug to cost more than $10,000 per year.
Huntsworth has stopped working with around 5% of clients in its Communications arm - which includes Grayling, Red and Citigate - as it exits "unprofitable" accounts, CEO Paul Taaffe has told PRWeek.
The Truth Initiative surveyed 9,000 young people to determine whether its campaign was really working.
Commercial chief to exit Bristol-Myers Squibb; Study: Wal-Mart $4 prescription plan a more affordable option for some Medicare patients; Trump administration pushes back on antibiotic use on farm animals.
Huntsworth has reported a 5.4% fall in like-for-like revenue at its PR agencies in the first half of 2018, led largely by declines at Grayling after the "elimination of unprofitable client contracts."
The holding company's net revenue jumped 5.6% in the second quarter.
Data on medical education spending show a continued increase in investment from the pharma and medical device industries.
Bayer to stop selling Essure; FDA approves Agios' leukemia treatment; Investor lawsuit targets Theranos.
This year's Cannes Lions festival made 9% less revenue than in 2017 owing to falls in both delegate numbers and awards entries resulting from Publicis Groupe sitting out the event and the organizers truncating the schedule.
Reid Connolly talks the benefits of buying San Francisco-based firm Giant.
More drugmakers vow to halt price increases; FDA considers allowing imported drugs in some cases; Trump administration examines rebates.
The holding company has launched a review of its Publicis Health Solutions business after a volatile Q2.
Healthcare decline weighs on Publicis Q2 earnings; Gottlieb releases biosimilar plan; Roche's lung cancer treatment shows positive results.
Being named among the MM&M Best Places to Work can help you stand out in the race for talent. Here's how the contest works.
Celgene's drug will now have time to establish itself in the market without generic competition.
The company posted a sales increase of 10.6% in the second quarter.
Novartis voluntarily halts price increases; Shkreli's former company considers name change; FDA issues guidance to modernize electronic health data in trials.
Payer Sciences is a health marketing agency that uses data and analytics to gather insights about payer behavior.
Prophet surveyed 240 healthcare organizations to find out where the industry is actually at on its shift to consumer centricity.
The holding company's overall revenue was up 1.8% in the period to $3.9 billion.
J&J beats expectations on Q2 earnings; AbbVie, Mylan sign U.S. license deal for Humira; Roche's new flu drug meets endpoints.
Huntsworth has continued its expansion by taking a majority stake in U.S. independent healthcare marketing agency Giant Creative Strategy for an initial sum of $72.2m.
Vital Health is driven by Ketchum's new analytics tool, Vital Diagnostics.
The Publicis-owned agency has laid off around 100 people in the U.S. alone this week
Dolin is overseeing offices in New York, New Jersey, Connecticut, and Canada.
MM&M Awards shortlist revealed; FDA approves first smallpox treatment; Another way Amazon could drive down healthcare costs.
Find out who made award-winning work this year.
Alexa could make it easier for doctors to squeeze CME programs into their busy schedules.
Doner will lead a branding effort for the health system that will roll out in 2019.
Wednesday's reorg was designed to position the company for growth in the face of the imminent patent cliff for megablockbuster Lyrica.
The agency said Jeremy Perrott violated the agency's code of conduct.
New report reveals large amount of opioids shipped to Missouri; Humana partners with Walgreens; Wyden requests details on Trump-Pfizer agreement
If you were unfamiliar with MediaMonks and want to know more about the company that Martin Sorrell has made his first capture, read on.
Tham Khai Meng has been with Ogilvy since 1999.
He's a veteran of Deep Focus, Wunderman, and ATTIK.
The government agency released its latest guidance this week.
Some Twitter accounts could lose millions of followers when the social platform purges large numbers of "locked" accounts this week.
Pfizer announces restructuring hours after about face on price hikes; Feds to slash funding for ACA "navigators"; Study finds rural states lag in combating heart disease.
In an interview with Campaign, Sir Martin Sorrell insisted his new company, S4 Capital, is listening to clients because they are "questioning" how agencies are delivering work.
Sir Martin Sorrell's S4 Capital has agreed to buy Dutch content business MediaMonks in a deal that is strikingly different from how he structured acquisitions at WPP.
Directing its reps to call on GPs with little to no opioid experience, Purdue introduced aggressive promotional tactics into the prescription opioid marketing playbook.
Biogen's recently soaring stock price can be attributed to investor optimism in one of the most stubborn areas of drug development.
CMS ends plan to make Novartis cancer treatment cheaper; Trump calls out Pfizer on Twitter for price hikes; News organizations sue to get federal opioid data.
The most comprehensive look at the pharma and healthcare agency world from MM&M.
There was a resetting of healthcare agency priorities in 2017, from income mix to what's keeping them up at night. But revenue continues its steady uptick as firms attempt to stay a step ahead of nontraditional players.
CEOs of the healthcare industry's largest holding companies discuss the future of the business and the importance of data privacy.
Everything you need to know about the agency world in medical marketing and communications - including revenue performance and profiles for the top 100 agencies - as well as the trends shaping the industry in general.
The deals follow last year's additions of Cambridge BioMarketing and MicroMass Communications.
Positive Alzheimer's trial sends Biogen shares surging; A year after crisis, analysts come around to AstraZeneca stock; Ironwood cuts 40 jobs ahead of split.
Amazon integration with PillPack could happen quickly; White House names DEA chief; Purdue stops marketing opioids in Canada.
11 questions for the GW CEO on the watershed moment.
WPP is also bidding for Dutch agency MediaMonks, pitting the group against its former chief executive, Martin Sorrell.
She is taking on the role alongside her role leading FCB Health medical communications subsidiary ProHealth.
UDG Healthcare makes two acquisitions; Lundbeck names Dunsire CEO; Accuracy of DTC genetic tests questioned.
Data marketing firm will become part of IPG Mediabrands portfolio.
The Office of Prescription Drug Promotion has sent its second warning letter of the year.
Fans hailed Disney's response following a strobe-light slip-up in the film Incredibles 2, but a patient group says it must go a step further as it seeks to recover from the blunder.
U.S. hospitals face staple drug shortage; Pfizer hikes price of 100 products; Federal judge blocks Kentucky work-requirement-for-Medicaid plan.
A survey from DRG Digital measured patient and doctor support for Amazon becoming an online pharmacy.
Fosamax appeal goes to Supreme Court; Gottlieb weighs in on Amazon-PillPack deal; Senator demands PhRMA, BIO address sexual harassment.
The campaign is appearing in millennial- and women-focused outlets such as Refinery29, Instagram, Bravo!, HGTV, and Cosmopolitan.
Amazon to acquire PillPack; Babylon Health says its AI diagnoses better than humans; Lilly's arthritis drug sees positive results.
The caregiver's journey is a highly personal one. A study examined their role in treatment decisions
Caregivers are intimately involved in patient health, and that includes deciding on treatments, a new study suggests.
Across the political spectrum, most Americans favor President Donald Trump's proposal to show drug prices in advertisements.
The lawyer for former spokesperson Phoebe Jonas said Bayer created "a big headache for everyone."
The partnerships came about after the Multiple Myeloma Research Foundation and Kantar Health conducted a study on cancer patients' knowledge gaps.
FDA gives priority review to new type of flu treatment; Lynparza shows positive trial data; Nurse practitioner lobby launches national campaign.